Grain Mines Surges 232% While Cue Biopharma Drops 31%
Grain Mines shares jumped 232% to $9.48, while Cue Biopharma fell 31.4% to $25.40 during Monday's trading session.
Key points
- Grain Mines shares surged 232.6% to $9.48, the largest gain in the tracked health care group.
- Cue Biopharma shares fell 31.4% to $25.40, the steepest drop among the listed securities.
- GRAIL and Invivyd both gained over 30%, with market caps of $3.6 billion and $222.5 million respectively.
Grain Mines (NASDAQ: GRML) posted the steepest gain among tracked health care securities on Monday, climbing 232.6% to close at $9.48. The move lifted the company's market capitalization to $9.0 million, representing a significant shift in valuation for the small-cap entity during the regular trading session.
Conversely, Cue Biopharma (NASDAQ: CUE) suffered the sharpest decline in the peer group, with shares retreating 31.4% to $25.40. The sell-off reduced the firm's market value to $269.1 million, marking a substantial erosion of shareholder equity in a single day compared to its prior close.
Small-Cap Gains Lead Sector Movers
GRAIL (NASDAQ: GRAL) followed the market leader with a 31.47% increase to $106.19, boosting its market cap to $3.6 billion. Invivyd (NASDAQ: IVVD) also posted strong results, rising 30.45% to $0.99 and reaching a valuation of $222.5 million.
Nanoviricides (AMEX: NNVC) advanced 23.59% to $1.75, while Regentis Biomaterials (AMEX: RGNT) climbed 19.33% to $2.16. Silexion Therapeutics (NASDAQ: SLXN) rounded out the top performers with a 14.53% gain to $0.50, resulting in a market cap of $2.4 million.
Biotech Losers Show Broad Declines
Moleculin Biotech (NASDAQ: MBRX) shares dropped 25.93% to $0.57, shrinking its market value to $15.0 million. IM Cannabis (NASDAQ: IMCC) fell 23.53% to $3.23, with a resulting market cap of just $2.5 million.
Apmimed (NASDAQ: APMD) declined 19.11% to $23.46, maintaining a larger market value of $1.2 billion despite the drop. Tempest Therapeutics (NASDAQ: TPST) lost 17.71% of its value to $0.80, while Baird Medical Investment (NASDAQ: BDMD) slid 16.03% to $0.88.
Market Data Context and Source
Benzinga reported these intraday movements as part of its daily health care sector monitoring. The data reflects regular session closes, highlighting the volatility present in both micro-cap and mid-cap pharmaceutical and biotechnology stocks.
